Screening for Cardiovascular Risk in Asymptomatic Patients

Journal of the American College of Cardiology

Volumn 55, Issue 12, 2010, Pages 1169-1177

  Berger, Jeffrey S ^a,b   Jordan, Courtney O ^c   Lloyd Jones, Donald ^d   Blumenthal, Roger S ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cardiovascular disease; myocardial infarction; prevention; risk score

Indexed keywords

ADULT TREATMENT PANEL III; ALGORITHM; ASSESSING CARDIOVASCULAR RISK TO SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FRAMINGHAM RISK SCORE; HEALTH CARE PERSONNEL; HUMAN; INSTRUMENT VALIDATION; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; POPULATION; PREDICTION; PRIORITY JOURNAL; QRESEARCH CARDIOVASCULAR RISK ALGORITHM; RECEIVER OPERATING CHARACTERISTIC; REVIEW; REYNOLDS RISK SCORE; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMATIC CORONARY RISK EVALUATION;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS;

EID: 77949283534     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.09.066     Document Type: Review

References (44)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-e181
2. D'Agostino Sr. R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 (2008) 743-753
3. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
4. Vasan R.S., Sullivan L.M., Wilson P.W., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 142 (2005) 393-402
5. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
6. Kannel W.B., McGee D., and Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 38 (1976) 46-51
7. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
8. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150 (2009) 396-404
9. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
10. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
11. Brindle P., Beswick A., Fahey T., and Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92 (2006) 1752-1759
12. Murabito J.M., D'Agostino R.B., Silbershatz H., and Wilson W.F. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 96 (1997) 44-49
13. Wolf P.A., D'Agostino R.B., Belanger A.J., and Kannel W.B. Probability of stroke: a risk profile from the Framingham study. Stroke 22 (1991) 312-318
14. Kannel W.B., D'Agostino R.B., Silbershatz H., Belanger A.J., Wilson P.W., and Levy D. Profile for estimating risk of heart failure. Arch Intern Med 159 (1999) 1197-1204
15. Lloyd-Jones D.M., Larson M.G., Beiser A., and Levy D. Lifetime risk of developing coronary heart disease. Lancet 353 (1999) 89-92
16. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006) 791-798
17. Pencina M.J., D'Agostino Sr. R.B., Larson M.G., Massaro J.M., and Vasan R.S. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119 (2009) 3078-3084
18. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
19. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
20. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
21. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007) 611-619
22. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., and Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008) 2243-2251
23. Woodward M., Brindle P., and Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 93 (2007) 172-176
24. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., and Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 335 (2007) 136
25. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., and Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94 (2008) 34-39
26. Greenland P., Smith Jr. S.C., and Grundy S.M. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104 (2001) 1863-1867
27. Mora S., Redberg R.F., Sharrett A.R., and Blumenthal R.S. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation 112 (2005) 1566-1572
28. Cohn J.N., and Duprez D.A. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol 52 (2008) 327-329
29. Greenland P., and Lloyd-Jones D. Defining a rational approach to screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 52 (2008) 330-332
30. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300 (2008) 197-208
31. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358 (2008) 1336-1345
32. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
33. Gibbons R.J., Balady G.J., Beasley J.W., et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 30 (1997) 260-311
34. Balady G.J., Larson M.G., Vasan R.S., Leip E.P., O'Donnell C.J., and Levy D. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation 110 (2004) 1920-1925
35. Gaziano T.A., Young C.R., Fitzmaurice G., Atwood S., and Gaziano J.M. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I follow-up study cohort. Lancet 371 (2008) 923-931
36. Berry J.D., Lloyd-Jones D.M., Garside D.B., and Greenland P. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J 154 (2007) 80-86
37. Berry J.D., Liu K., Folsom A.R., et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 119 (2009) 382-389
38. Brindle P., Emberson J., Lampe F., et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327 (2003) 1267
39. Liu J., Hong Y., D'Agostino Sr. R.B., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291 (2004) 2591-2599
40. Grundy S.M., D'Agostino Sr. R.B., Mosca L., et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation 104 (2001) 491-496
41. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
42. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
43. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
44. Grundy S.M., Pasternak R., Greenland P., Smith Jr. S., and Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 (1999) 1481-1492